4 results · Page 1 of 1

Swipe the table sideways for more columns.

TrialConditionsStatusPhaseUpdatedMore infoNCT ID
Fruquintinib in Patients With Metastatic Colorectal CancerDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, colonic disorder, colorectal neoplasm, digestive system disorder, digestive system neoplasm, intestinal disorder, neoplasm, rectal disorderRecruitingNot stated2026-09-04NCT06787105
A Study of Trastuzumab DeRuxtecan for Patients With Advanced HER2-pOsitive GaStric or GastroesoPhageal Junction AdEnocarcinoma Who Have Received a PrIor Trastuzumab-based Regimen Accompanied by a Disease RegistrY of Patients Treated With Conventional Therapies (PROSPERITY)HER2-positive Advanced Gastric Cancer; HER2-positive Gastroesophageal Junction AdenocarcinomaActive, not recruitingNot stated2026-08-20NCT05993234
Platform Trial Evaluating Treatment of Neoadjuvant Trastuzumab-deruxtecan Containing Combination Therapies for HER2+, Resectable Esophagogastric AdenocarcinomaEsophagogastric AdenocarcinomaActive, not recruitingPhase 1 / Phase 22026-04-21NCT06731803
A Phase Ib Trial Evaluating the Safety and Activity of Neoadjuvant Combination of Tislelizumab Plus FLOT for Resectable Esophagogastric AdenocarcinomaDigestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, digestive system disorder, digestive system neoplasm, esophageal adenocarcinoma, gastric adenocarcinoma, gastric neoplasm, gastroesophageal junction adenocarcinoma, neoplasm, stomach disorderRecruitingPhase 12025-12-19NCT07059299